Falling demand, generic competition in a key molecule and weak customer ordering trends continue to weigh on PI Industries’ CSM business, raising questions over the pace of recovery in FY27.
Source link
Falling demand, generic competition in a key molecule and weak customer ordering trends continue to weigh on PI Industries’ CSM business, raising questions over the pace of recovery in FY27.
Source link